AUG 28, 2015 9:39 PM PDT

Promising Drug Target in Pancreatic Cancer Cells

WRITTEN BY: Ilene Schneider
Pancreatic cancer, the fourth deadliest cancer in the U.S., is very hard to detect in its early stages. Rarely diagnosed early and usually spreading rapidly, the disease has a poor prognosis. University of Houston researchers are seeking to develop drugs to enable physicians to prolong patient survival and, possibly, even eradicate pancreatic cancer, according to an article in Drug Discovery & Development
Professor Chin-Yo Lin works with Ph.D. student Sridevi Addanki in his lab at the Center for Nuclear Receptors and Cell Signaling in the College of Natural Sciences and Mathematics at the University of Houston. 
According to cancer biologist Chin-Yo Lin, an assistant professor with the UH Center for Nuclear Receptors and Cell Signaling (CNRCS), "Our research on the role of liver X receptors, or LXRs, in pancreatic cancer cells points to a promising target and strategy in the treatment of pancreatic cancer. We examined the levels of LXRs in patient tumor samples and studied the effects of candidate drug compounds targeting LXRs on cultured pancreatic cancer cells."
 
Lin explained that liver X receptors are key regulators of cholesterol, glucose metabolism and inflammatory response modulation. In collaboration with CNRCS director Dr. Jan-Åke Gustafsson, a pioneer in the discovery of LXRs and the Robert A. Welch Professor in Biology and Biochemistry in the UH College of Natural Sciences and Mathematics, Lin has helped to amass evidence to implicate the involvement of LXRs in numerous malignancies.
 
The researchers expect their ongoing studies to help determine whether LXRs are expressed in all tumors or a specific subset of tumors that could be sensitive to drugs targeting LXRs. Another objective is to determine the effects of the drugs on pancreatic tumors in mouse models that are similar to those found in humans. Eventually, they anticipate using the knowledge from these studies to develop better drugs to target LXRs in pancreatic cancer and other malignancies.
 
The team has done some preliminary studies of LXR expression in patient tumor samples and is preparing to investigate more samples. Recent studies demonstrated that chemical compounds targeting LXRs can retard the growth of tumors in murine models transplanted with human tumor cells.
 
As Lin said, "Our findings point to a class of receptors that can be precisely targeted by drug compounds and are expected to stimulate both basic and translational research on their functions and application as a drug target. Long-term goals are to develop additional drug compounds and clinical testing in human subjects, which will require several more years of research."
 
He concluded, "Our next steps are to collect more information from patient samples and data from pre-clinical studies. Based on the results, we will then move forward with clinical studies using existing compounds or partner with biotech or pharmaceutical companies to develop better drug candidates."
 
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
MAY 19, 2020
Cancer
Great ape genomes closer to human tumors than human genomes
MAY 19, 2020
Great ape genomes closer to human tumors than human genomes
A new study analyzing cancer from an evolutionary perspective reports that the distribution of mutations in human tumors ...
MAY 23, 2020
Cancer
A New Biomarker to Identify a Triple Negative Breast Cancer Prognosis
MAY 23, 2020
A New Biomarker to Identify a Triple Negative Breast Cancer Prognosis
Breast cancer, one of the most common cancers in the world, are commonly separated into one of several sub-types. These ...
JUN 06, 2020
Cancer
Developing a Platform to Efficiently Test Antibody-Drug Conjugates
JUN 06, 2020
Developing a Platform to Efficiently Test Antibody-Drug Conjugates
Cancer has been one of the most persistent diseases modern medicine has faced. Due to its nature, treatments are often t ...
JUN 08, 2020
Cell & Molecular Biology
How Cancer Cells Use Inflammation as a Shield Against Viruses
JUN 08, 2020
How Cancer Cells Use Inflammation as a Shield Against Viruses
Microorganisms called oncolytic viruses can infect and kill cancer cells while leaving healthy cells alone.
JUN 16, 2020
Cancer
Wearable patch for melanoma patients
JUN 16, 2020
Wearable patch for melanoma patients
Research published in the journal ACS Nano describes a wearable patch that can be used to lessen side effects from chemo ...
JUL 15, 2020
Immunology
Immune Memory to Thwart Recurring Cancer
JUL 15, 2020
Immune Memory to Thwart Recurring Cancer
Preventing cancer from returning in the body is an integral part of any anti-cancer treatment plan. New discoveries from ...
Loading Comments...